Internal Medicine, Rheumatology · Crossville, TN
NPI
1982666012
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
49 Cleveland St, Suite 350
Crossville, TN, 38555
Phone (931) 456-5515
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
164,886 services
Medicare patients, 2024
670
Average age 71
Drug cost, 2024
$9.3M
10,480 prescriptions
Company payments, 2025
$2,847
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sivalingam Kanagasegar was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 59,200 times for 21 patients. In total Sivalingam Kanagasegar billed 164,886 services in 45 codes, and Medicare paid $2.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-05-30.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 59,200 | 21 | $3.58 | $212K |
| J3262 Injection, tocilizumab, 1 mg | Office | 34,760 | 13 | $4.63 | $161K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 28,950 | 42 | $8.76 | $254K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 23,750 | 34 | $33.92 | $806K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,566 | 32 | $0.10 | $244 |
| 99214 Office E&M - Established | Office | 1,452 | 601 | $86.02 | $125K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 683 | 20 | $0.22 | $151 |
| 96413 Chemotherapy Administration | Office | 590 | 89 | $87.43 | $52K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 507 | 81 | $0.71 | $359 |
| 96401 Chemotherapy Administration | Office | 346 | 26 | $49.70 | $17K |
| 99204 Office E&M - New | Office | 186 | 186 | $116.61 | $22K |
| 99213 Office E&M - Established | Office | 149 | 90 | $64.19 | $9,564 |
| 96375 Injection Administration | Office | 94 | 22 | $10.73 | $1,008 |
| 20610 Joint Injection | Office | 93 | 62 | $46.17 | $4,294 |
| 98980 Care Management/Coordination | Office | 64 | 15 | $34.70 | $2,221 |
By year: 2022 $1.8M for 153,923 services; 2023 $2.6M for 184,417 services; 2024 $2.2M for 164,886 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sivalingam Kanagasegar prescribed most often to Medicare patients was Prednisone, with 854 prescriptions and refills. In total Sivalingam Kanagasegar wrote 10,480 Medicare prescriptions that cost $9.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 854 | 1,113 | 312 | $3,926 |
| Methotrexate Methotrexate Sodium | 798 | 1,379 | 229 | $21K |
| Hydroxychloroquine Sulfate Generic | 705 | 1,181 | 178 | $28K |
| Gabapentin Generic | 704 | 852 | 159 | $9,635 |
| Duloxetine Hcl Generic | 638 | 1,040 | 148 | $12K |
| Celecoxib Generic | 584 | 935 | 164 | $11K |
| Tramadol Hcl Generic | 453 | 453 | 119 | $2,959 |
| Leflunomide Generic | 422 | 775 | 116 | $33K |
| Pregabalin Generic | 356 | 420 | 62 | $6,637 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 322 | 322 | 102 | $7,206 |
| Meloxicam Generic | 318 | 480 | 95 | $1,266 |
| Enbrel Sureclick Etanercept | 311 | 316 | 36 | $2.4M |
| Folic Acid Generic | 311 | 588 | 91 | $1,216 |
| Tizanidine Hcl Generic | 310 | 521 | 108 | $2,523 |
| Diclofenac Sodium Generic | 286 | 476 | 94 | $5,899 |
Brand drugs: 1,599 claims; generic drugs: 8,857 claims; opioid claims: 908.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sivalingam Kanagasegar $2,847 ($2,559 in general payments such as food, travel and fees and $288 for research) from 16 companies. The largest payer was Abbvie Inc. with $629.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 43 | $629 |
| Amgen Inc. AMGN | 22 | $423 |
| UCB, Inc. UCB.BR | 18 | $323 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $319 |
| Janssen Biotech, Inc. JNJ | 15 | $299 |
| Eli Lilly and Company LLY | 1 | $288 |
| Genzyme Corporation SNY | 6 | $122 |
| GlaxoSmithKline, LLC. GSK | 5 | $87.9 |
| Fresenius Kabi USA, LLC | 4 | $71.38 |
| Pfizer Inc. PFE | 4 | $66.76 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.